Interleukin-17 (IL-17) is an essential proinflammatory cytokine, which is mainly secreted by
the CD4+ helper T cells (Th17 cells) and subsets of innate lymphoid cells. IL-17A is …

Psoriasis is a chronic, immune-mediated, inflammatory disease that is pathogenically driven
by proinflammatory cytokines. This article reviews the immunologic role of interleukin (IL)-17 …

Background There is an unmet need for a treatment for psoriasis that results in complete
skin clearance with a reliably quick response. Bimekizumab is a monoclonal IgG1 antibody …

Background The use of monoclonal antibodies has changed the treatment of several
immune-mediated inflammatory diseases, including psoriasis. However, these large …

Background Psoriasis is a chronic, systemic immune‐mediated disease characterized by
development of erythematous, indurated, scaly, pruritic and often painful skin plaques …

Objective Use of the frailty index to measure an accumulation of deficits has been proven a
valuable method for identifying elderly people at risk for increased vulnerability, disease …

Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both
interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared …

Sjogren's syndrome (SS) is a chronic autoimmune disease accompanied by multiple
lesions. The main manifestations include dryness of the mouth and eyes, along with …

Numerous scientific studies in recent years have shown significant skin and gut dysbiosis
among patients with psoriasis. A significant decrease in microbiome alpha-diversity …

The excellent clinical efficacy of anti-interleukin 17A (IL-17A) biologics on psoriasis indicates
a crucial pathogenic role of IL-17A in this autoinflammatory skin disease. IL-17A accelerates …